Abstract 1715
Background
Small cell bladder cancer (SCBC) is rare and accounts for <1% of all bladder carcinomas. It is aggressive and outcomes are poor due to early metastatic spread. Owing to its rarity, there is currently no standardised UK management pathway and treatments vary between institutions.
Methods
We conducted a retrospective analysis of all patients presenting with SCBC across 26 UK institutions between 1/1/2006 - 1/1/2016. We report on the patient characteristics, treatment received and clinical outcome. Data cut-off date is 1/2/2018.
Results
409 eligible patients (pts) from 26 UK institutions were identified. 75.1% were male. Median age was 71 years (range 35 - 96). 189/409 pts (46.2%) had pure small cell cancer. At data cut-off, 301/409 pts (73.6%) have died. Median overall survival (OS) was 15.9 months (range 9 - 4230 days). 200/409 pts (48.9%) presented with bladder only disease (N0 M0). Median OS of N0 M0 disease was 28.3 months vs. 12.7 months in N+/ M+ disease. Within the N0 M0 group, 61/200 pts (30.5%) had cystectomy and 104/200 pts (52.0%) had radiotherapy. The most common radiotherapy dose schedules used were 64Gy in 32 fractions and 55Gy in 20 fractions. Median OS of the cystectomy group was 26.7 months vs 30.0 months for radiotherapy. 247/409 pts (60.4%) received primary chemotherapy. Median time from diagnosis to first chemotherapy date was 47 days (range 5 - 124 days). The regimens used include carboplatin and etoposide (54.6%), cisplatin and etoposide (17.0%), cisplatin and gemcitabine (14.2%), carboplatin and gemcitabine (5.3%), other (3.6%). Median OS of pts who received primary chemotherapy was 21.6 months vs. 11.3 months in those who received no chemotherapy. Only 6 pts (1.5%) were identified to have brain metastases.
Conclusions
This is the largest retrospective study of unselected small cell cancer bladder population to date. These patients have a poor prognosis and brain metastases were rare (1.5%). Median OS was better in the chemotherapy than the non-chemotherapy group. Our results are in keeping with other studies which showed similar outcome between cystectomy and radiotherapy in patients with bladder only disease. UK national consensus guidelines are now being set up to standardise therapeutic approach for this rare disease entity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract